MJ33-OH lithium is used as a specific, active site-directed, competitive, and reversible inhibitor of phospholipase A2 (PLA2), particularly targeting the calcium-independent PLA2 (iPLA2) activity of Prdx6; it plays a significant role in mitigating inflammatory brain injury by significantly blocking the increase of IL-1β, IL-17, and IL-23 in rats; and in combination with Prdx6 siRNA, it downregulates the mRNA and protein expression of NF-κB, iNOS, and COX-2.